CXC chemokines in angiogenesis

By J. Belperio, Michael P. Keane, D. Arenberg, Christina L. Addison, Jan E. Ehlert, M. Burdick, R. Strieter. Journal of Leukocyte Biology, 2000

1,144 citations recorded by the source corpus.

A variety of factors have been identified that regulate angiogenesis, including the CXC chemokine family. The CXC chemokines are a unique family of cytokines for their ability to behave in a disparate manner in the regulation of angiogenesis. CXC chemokines have four highly conserved cysteine amino acid residues, with the first two cysteine amino acid residues separated by one non‐conserved amino acid residue (i.e., CXC). A second structural domain within this family determines their angiogenic potential. The NH2 terminus of the majority of the CXC chemokines contains three amino acid residues (Glu‐Leu‐Arg: the ELR motif), which precedes the first cysteine amino acid residue of the primary structure of these cytokines. Members that contain the ELR motif (ELR+) are potent promoters of angiogenesis. In contrast, members that are inducible by interferons and lack the ELR motif (ELR−) are potent inhibitors of angiogenesis. This difference in angiogenic activity may impact on the pathogenesis of a variety of disorders.

Subfields: Immunology and Allergy, Oncology

View Paper: https://www.semanticscholar.org/paper/ffe5447cb0ea00f5491a91ff7d80272b2582410e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

Chemokines in cutaneous wound healing (2001, background): “The work of Strieter and colleagues (see [13] for review) demonstrated that CXC chemokines, which contain a Glu-Leu-Arg (ELR) motif [54] adjacent to their first cysteine amino acid in the NH2 terminus, are potent promoters of angiogenesis.”
CXCL10/IP-10 in Infectious Diseases Pathogenesis and Potential Therapeutic Implications (2011, neutral): “As an ELR-negative CXC chemokine, CXCL10 exerts important effects in anti-tumor effects which cannot be omitted when we review angiostatic functions of CXCL10 [45–47].”
PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing (2008, background): “This cytokine inhibits the migration of dermal fibroblasts by blocking their release from the substratum regulated by IP-10 inhibition of EGF and heparin-binding EGF-like growth factor receptor-mediated calpain activity.44 In addition, it has been shown that IP10 inhibits angiogenesis (reviewed in B”
An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 (2003, background): “1538 Cell Growth Inhibition via a Novel Type of Chemokine Receptor (HMVEC) * are mediated by the CXC chemokine receptor 3 (CXCR3; 4–6, 11–13), whereas the receptor for CXCL4 has not yet been identified (4, 6).”
Evolving functions of endothelial cells in inflammation (2007, background): “Certain chemokines, such as CXCL8, also have angiogenic propertie”
Structure, function, and inhibition of chemokines. (2002, background): “Nuclear magnetic resonance solution structure of truncated human GRObeta [5–73] and its structural comparison with CXC chemokine family members GROalpha and IL-8.”
The role of CXC chemokines and their receptors in cancer. (2008, background): “There are at least three splice variants of CXCR3, named CXCR3-A, CXCR3-B and CXCR3-alt [91].”